Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01892397 · ClinicalTrials.gov registry record · NA

Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma

A NA study of Brain Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
NA
Development phase
6
Enrollment target
9
Study locations

NCT01892397 is a NA study of Brain Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 6 participants, below the 507-participant average among 47 other Brain Cancer trials with a reported enrollment target (99% lower). The trial reports 9 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01892397, a NA study of Brain Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
6 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this study is to find out what effects, good or bad, the Optune device has on the patient and meningioma. This study is being done because currently there are no proven effective medical treatments for a progressive meningioma that has failed surgery and/or radiation. The study uses an experimental device called Optune. Optune is "experimental" because it has not been approved by the U.S. Food and Drug Administration (FDA) for this type of tumor, although it has been approved for a different type of brain tumor.

Conditions Studied

Brain Cancer

Interventions

  • DEVICE Optune (NovoTTF-100A)

Study Locations (9)

New York

  • Memorial Sloan Kettering Cancer Center at Commack - Commack
  • Memorial Sloan Kettering West Harrison - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Columbia University - New York

California

  • Cedars-Sinai Medical Center - Los Angeles

Colorado

  • University of Colorado - Denver

Florida

  • University of Miami - Miami

New Jersey

  • Memorial Sloan Kettering Cancer Center - Basking Ridge

Ohio

  • University of Cincinnati - Cincinnati

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2013-06
Est. Completion 2026-06
Phase NA

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01892397

The ClinicalTrials.gov registry entry for NCT01892397 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 507-participant average among 47 other Brain Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain Cancer appearing as the primary indexed condition, and to 1 intervention - of which Optune (NovoTTF-100A) is the first listed.

NCT01892397 reports 9 study locations spanning 6 distinct geographic areas - top geographies include New York, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT01892397 about?

NCT01892397 is a clinical study titled "Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma". The purpose of this study is to find out what effects, good or bad, the Optune device has on the patient and meningioma. This study is being done because currently there are no proven effective medical treatments for a progressive meningioma that has failed surgery and/or radiation. The study uses a...

What is the current status of trial NCT01892397?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 6 participants. The study started on 2013-06. Estimated completion is 2026-06.

What conditions does trial NCT01892397 study?

This clinical trial studies the following conditions: Brain Cancer.

What interventions are being tested in trial NCT01892397?

The interventions under investigation include: Optune (NovoTTF-100A) (DEVICE).

Who is sponsoring clinical trial NCT01892397?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01892397 being conducted?

This trial has 9 study locations across California, Colorado, Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Brain Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Brain Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.